INTRODUCTION
Oncogene-induced tumor suppression presents an efficient cellautonomous restraint to tumor formation in the face of mitogenic signaling by deregulated proto-oncogenes (Evan et al., 2005) . MYC serves as a paradigm example of this phenomenon (Askew et al., 1991; Evan et al., 1992; Strasser et al., 1990) : deregulated MYC expression simultaneously drives both cell proliferation and apoptosis, with the relative rates of each ultimately determining whether the affected population expands or contracts. Importantly, the threshold level of MYC required to engage apoptosis is set higher than the level required to initiate cell proliferation, thereby enabling healthy cells to proliferate in response to physiological signaling, all the while maintaining an effective barrier to supraphysiological (i.e., oncogenic) MYC expression .
MYC-induced apoptosis is widely thought to be mediated by the ARF-p53 pathway. Overexpression of MYC induces accumulation of p19ARF (p14ARF in human cells), which counteracts MDM2-mediated degradation of p53 Stott et al., 1998; Zindy et al., 1998; Eischen et al., 1999; Schmitt et al., 1999) . Activated p53 in turn induces apoptosis via transcriptional upregulation of BH3-only proteins PUMA and NOXA (Nakano and Vousden, 2001; Villunger et al., 2003) . However, apoptosis is not the only possible outcome from p53 stabilization, and recent work has shown that acetylation of K117 (K120 in human p53) is also specifically required for induction of NOXA, PUMA, and thereby apoptosis. Significantly, a K117R mutant p53 is still competent to induce cell-cycle arrest, senescence, and tumor suppression (Li et al., 2012) . Thus, a dual-signal mechanism governs cell fate in response to p53 accumulation. Additionally, several groups have reported MYC-induced apoptosis in the absence of either p19ARF or p53, strongly suggesting the existence of an alternative pathway to MYC-induced killing (Hsu et al., 1995; Blyth et al., 2000; Eischen et al., 2001; Finch et al., 2006) .
A growing body of evidence supports a central role for the BCL2 homologous (BH) family of proteins in mediating MYCinduced apoptosis. This family of proteins is subdivided into antiapoptotic (e.g., BCL2, BCLXL, MCL1, and A1), proapoptotic BH3-only (including BIM, BID, BAD, PUMA, and NOXA), and effector BH3 proteins, BAX and BAK. In response to proapoptotic stimuli, BAX and BAK oligomerize to cause mitochondrial outer membrane permeabilization, triggering release of cytochrome c, SMAC/DIABLO, and consequent activation of effector caspases (Sarosiek et al., 2013b; Czabotar et al., 2014) . Antiapoptotic BH family proteins buffer against pore formation, whereas proapoptotic BH3-only proteins counteract this buffering and, in some instances, can directly stimulate BAX/BAK oligomerization (Llambi et al., 2011; Sarosiek et al., 2013a) .
MYC-induced apoptosis requires BAX/BAK Juin et al., 2002) , release of cytochrome c (Juin et al., 1999) , and activation of effector caspases, contingent upon tonic signaling through CD95 (Hueber et al., 1997) , and is blocked by coexpression of antiapoptotic family proteins (Bissonnette et al., 1992; Fanidi et al., 1992; Pelengaris et al., 2002) . Conversely, MYCdependent suppression of BCLXL and BCL2 sensitizes cells to g-irradiation-induced apoptosis (Eischen et al., 2001; Maclean et al., 2003) . The recent identification of BIM as a transcriptional target of MYC suggests that this BH3-only protein may directly mediate MYC's proapoptotic signal (Campone et al., 2011; Lee et al., 2013) . MYC induces BIM accumulation in Burkitt's lymphoma, and MYC point mutants that fail to induce BIM also fail to induce apoptosis. Notably, such mutants are fully competent to induce p19ARF, p53, and indeed accumulation of p21 downstream of p53 (Hemann et al., 2005) . These observations prompted us to reexamine the relative contributions of p19ARF and BIM to MYC-induced apoptosis. We employed here a single transgenic model to systematically evaluate MYC-induced apoptosis in a variety of settings. Our data reveal that BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues.
RESULTS

BIM Is Required for MYC-Induced Apoptosis in the Intestine
To investigate the mechanistic requirements of MYC-induced apoptosis in multiple tissues, we used a previously described Rosa26-MycER T2 mouse line that ubiquitously expresses a latent, ;Arf null (n = 3) mice. Two-tailed, unpaired t tests were used to determine statistical significance: **p < 0.01; ***p < 0.001; ns, not significant. See also Figure S1 .
tamoxifen ( Figure S1A ) . Tissues were harvested within 24 hr of the final injection, and apoptotic cells were identified by nuclear terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining (Figure 1 ). In the small intestine, MYC-induced apoptosis is largely restricted to the crypt region and was modestly reduced by Arf deletion. In the large intestine, where MYC-induced apoptosis is more widely distributed, apoptosis was unaffected by p19ARF loss. Deletion of Bim on the other hand abrogated MYC-induced apoptosis in these two tissues. BIM is thought to act primarily via broad antagonism of prosurvival BH3 family proteins including BCL2, BCLXL, and MCL1, although direct activation of the effector BH3 protein BAX likely contributes to BIM's potency (Sarosiek et al., 2013a) . PUMA is the primary BH3-only effector of p53-mediated apoptosis in the intestine (Yu et al., 2003) . Like BIM, PUMA is a broad specificity antagonist of prosurvival BH3 proteins, and like BIM deletion, PUMA deletion accelerates MYC-induced B cell lymphomagenesis (Michalak et al., 2009 mice revealed modestly reduced MYC-driven apoptosis in the small intestine, relative to PUMA-replete controls, whereas deletion of Puma had no effect on MYC-induced apoptosis in the large intestine ( Figures S1B-S1D) . Thus, among the proapoptotic BH3-only proteins, there is a specific requirement for BIM during MYC-induced apoptosis in these tissues. ;Arf null (n = 5) mice. Two-tailed, unpaired t tests were used to determine statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant. See also Figure S2 .
does sensitize cells to additional proapoptotic stimuli, such as doxorubicin (Figure 2) . Again, deletion of Bim abrogated the apoptotic response in all three tissues, whereas disruption of Arf had no effect. Deletion of Puma protected all three tissues to the same extent as Bim loss, confirming the cooperative nature of death in response to these two proapoptotic stimuli ( Figure S2A) . Notably, however, death induced by doxorubicin alone, confined in these experiments to the small intestine, is unaffected by Bim deletion but does require PUMA, as expected for a canonical p53-mediated response to DNA damage ( Figure S2B ). Moreover, doxorubicin neither induces BIM nor augments MYC induction of BIM protein, and Bim is not required for doxorubicin-induced killing in mouse embryonic fibroblasts (MEFs) (Figures S2C and S2D) . Thus, MYC and doxorubicin elicit apoptotic signaling via induction of distinct proapoptotic BH3 family proteins. Figure 3A ). Whole-genome chromatin immunoprecipitationcoupled deep sequencing (ChIP-seq) analysis revealed 4-OHTinduced binding of MycER to the BIM (BCL2L11) promoter in human MCF10A cells, and constitutive occupation of the Bim promoter by endogenous MYC in murine KPC pancreatic tumor cells (Morton et al., 2010) , comparable to binding at the canonical MYC target gene ODC1 (Figures 3B and S3C ). Gene-specific ChIP with the N262 antibody, which recognizes both endogenous murine MYC and exogenous MycER the contribution of p19ARF and BIM to MYC-induced apoptosis in this system, and measured apoptosis 30 and 72 hr after addition of 4-OHT to cells in low serum. Again, deletion of Bim suppressed MYC-induced apoptosis, whereas deletion of Arf did not ( Figures  3D, 3E , S3E, and S3F). Although serum deprivation alone did induce low levels of BIM expression, further induction of BIM by MYC was unaffected by serum levels ( Figure S3G) , and, notably, Bim deletion had no effect on the basal level of apoptosis induced by culturing MEFs in low serum. Moreover, deletion of Bim suppressed MYC sensitization of MEFs cultured in growth media to both g-irradiation-and ABT-737-induced apoptosis ( Figure S4 ), and Bim null MEFs showed increased clonogenic survival in the presence of deregulated MYC ( Figure 3F (Figure 4 ). This result is in broad agreement with a previous report that haploinsufficiency for Bim accelerates MYC-induced lymphomagenesis and supports a model where a threshold level of BIM is required to mediate MYC's apoptotic signal (Egle et al., 2004) .
MYC Directly Regulates BIM Expression
DISCUSSION
We present here evidence that the BH3-only protein BIM is the primary mediator of MYC-induced apoptosis in vivo and in vitro. We show MYC binding to the BIM promoter, acutely elevating BIM expression, and provide genetic evidence that BIM is required for MYC-induced apoptosis under multiple circumstances and in multiple solid tissues. Strikingly, deletion of Puma fails to phenocopy Bim deletion when apoptosis is induced by MYC alone, despite the fact that loss of PUMA, like loss of BIM, has been shown to accelerate MYC-induced lymphomagenesis and despite similarities in their mechanism of action (Egle et al., 2004; Czabotar et al., 2014) . Conversely, Bim deletion fails to phenocopy PUMA loss during doxorubicin-induced apoptosis in the small intestine. However, both ;Bim heterozygous (n = 3) mice. Two-tailed, unpaired t tests were used to determine statistical significance: *p < 0.05; **p < 0.01; ***p < 0.001.
BIM and PUMA are required for the synthetic induction of apoptosis driven by the combination of MYC and doxorubicin in tissues where either alone is insufficient to trigger cell death. The differential sensitivities of various tissues to experimental apoptotic stimuli are partly explained by differences in MycER T2 expression levels ) but also likely reflect the level of apoptotic priming intrinsic to each tissue, where differential expression of specific antiapoptotic BH3 proteins may determine the relative potency of individual proapoptotic BH3 proteins (Ni Chonghaile et al., 2011) . Thus, these results argue for a model wherein individual BH3-only proteins have evolved to transduce specific proapoptotic signals yet can combine to overcome antiapoptotic buffering.
Therapeutic Implications MYC family oncogenes are among the most frequently overexpressed genes across a broad spectrum of human cancers. Effective MYC-centric therapies could therefore have a tremendous impact on cancer survival rates. Several strategies to target MYC are being actively pursued, including direct suppression of MYC protein (Soucek et al., 2008; Popov et al., 2010) , transcriptional suppression (Zuber et al., 2011) , and synthetic lethality (Goga et al., 2007; Liu et al., 2012; Kemp and Grandori, 2013) , and it is likely that combinatorial strategies will ultimately prove the most effective. A rational strategy to exploit the intrinsic apoptotic potential of MYC-overexpressing cells would complement these efforts greatly. BH3 mimetics suppress lymphomagenesis in Em-MYC mice, even in the absence of a functional p53 pathway (Kelly et al., 2013 (Kelly et al., , 2014 . Given the prevalence of MYC overexpression in human cancers, our data support the approach of augmenting the intrinsic apoptotic response through the use of BH3 mimetics and suggest that this strategy may elicit therapeutic benefits in a spectrum of solid tumor types.
